Mr Dimitrios Volanis

Job title

Locum consultant urologist

Qualifications

MD, PhD, FEBU

GMC Number

6131667

Contact details

Phone number: 020 8216 4795

PA/secretary email address: michelle.martin8@nhs.net

Fax: 020 8216 4501

Related services

Urology

Biography

Mr Volanis was appointed to the Royal Free London in 2015 having completed a fellowship at Cambridge in robotic surgery. His special interest is bladder and prostate cancer and runs weekly clinics for newly diagnosed patients. His research is focused on the molecular mechanisms that govern the development and progression of bladder cancer.

Publications

  • Evaluation of neutrophil gelatinase-associated lipocalin, interleukin-18 and cystatin C as molecular markers before and after unilateral shock wave lithotripsy. Kardakos IS, Volanis DI, Kalikaki A, Tzortzis VP, Serafetinides EN, Melekos MD, Delakas DS.Urology 2014 Oct;84(4):783-8
  • Incidence of needle-tract seeding following prostate biopsy for suspected cancer: a review of the literature.Volanis D, Neal DE, Warren AY, Gnanapragasam VJ.BJU Int. 2015 May;115(5):698-704
  • Comparative oncologic and toxicity outcomes of salvage prostatectomy versus non-surgical therapies for radio-recurrent prostate cancer: A meta-regression analysis. Philippou Y., Parker R., Volanis D.,GnanapragasamV.European Urology Focus (article in press)
  • Role of the angiogenic components VGEFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder.Zaravinos A, Volanis D, Lambrou GI, Delakas D, Spandidos DA. Oncol Rep. 2012 Oct;28(4):1159-66
  • Endoscopic Nephron-Sparing Management of Superficial Low-Grade Upper Urinary Tract Urothelial Carcinoma. Dimitrios Volanis, Ranan DasGupta, Anup Pate. European Urology Review, 2012;7(1):10-4
  • Expression of MiRNAs Involved in Angiogenesis, Tumor Cell Proliferation, Tumor Suppressor Inhibition, EMT and Activation of Metastasis in Urinary Bladder Cancer. Zaravinos A, Rodojicic J, Lambrou GI, Volanis D, Delakas D, Stathopoulos EN., Spandidos DA.J. Urol. 2012 Aug;188(2):615-23
  • Molecular mechanisms in urinary bladder carcinogenesis.Volanis D, Papadopoulos G, Gialas Ι, Doumas K, Delakas D. J BUON. 2011 Oct-Dec;16(4):589-601.
  • Expression profile of Rho kinases in urinary bladder cancer. Volanis D, Zaravinos A, Kadiyska T, Delakas D, Zoumpourlis V, Spandidos DA. J. BUON 2011 Jul-Sep; 16(3):511-521
  • Spotlight on differentially expressed genes in urinary bladder cancer. Zaravinos A, Labrou GI, Volanis D, Delakas D, Spandidos DA. PloS One. 2011 Apr 5;6(4):e18255
  • Plasmacytoid urothelial carcinoma of the bladder: a    rare malignancy. Philippou P, Karyotis I, Volanis D, Ploumides A, Delakas D. Urol Int. 2011;86(3):370-2
  • Prospective comparative study of endoscopic management of bladder lithiasis: is prostate surgery a necessary adjunct? Philippou P, Volanis D, Karyotis I, Serafetinidis E, Delakas D. Urology. 2011 Jul;78(1):43-7
  • Safety of ultrasound-guided transrectal extended biopsy in patients receiving low-dose aspirin. Karyotis I, Philippou P, Volanis D, Serafetinidis E, Delakas D. Int Braz J Urol. 2010 May-Jun;36(3):308-16.
  • Environmental factors and genetic susceptibility promote urinary bladder cancer. Volanis D., Kadyiska T., Galanis A., Delakas D., Logotheti S., Zoumpourlis V.Toxicol Lett. 2010 15;193(2):131-7
  • Pheochromocytoma of the urinary bladder : Report of two cases and review of literature. Siatelis A., Konstantinidis C., Volanis D., Leontara V., Thoma-Tsagli E., Delakas D. Minerva Urol Nefrol 2008 Jun;60(2):137-140